This article is more than 5 years old. Information may no longer be current.
Ocugen enters partnership with CanSinoBIO, completes Histogenics merger
Click Here to Manage Email Alerts
Ocugen announced a strategic partnership with CanSino Biologics for gene therapy candidates and also the completion of its merger with Histogenics.
CanSinoBIO will provide CMC development and clinical supplies for the development of OCU400, Ocugen’s first gene therapy product in its modifier gene therapy platform, according to a press release. The agreement provides commercialization rights to CanSinoBIO in greater China and allows CanSinoBIO the option to support commercial manufacture for Ocugen.
Ocugen has received orphan drug designations for OCU400 for the treatment of NR3E3 mutation-associated retinal degeneration and CEP290 mutation-associated retinal disease.
The therapy consists of a functional copy of the nuclear hormone receptor gene NR2E3 and is delivered to target cells in the retina using an adeno-associated viral vector.
Regarding the merger with Histogenics, Ocugen is now trading on the Nasdaq Capital Market under the ticker symbol “OCGN,” according to a separate press release. Shankar Musunuri, PhD, MBA, will serve as chairman, CEO and co-founder of the company.